Chlorphenamine

Identification

Name

Chlorphenamine

Accession Number

DB01114  (APRD00001, DB09440)

Type

Small Molecule

Groups

Approved

Description

A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB01114 (Chlorphenamine)

×

Close

Synonyms

• 1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
• 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine
• 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
• 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
• Chlorophenylpyridamine
• Chlorphenamin
• Chlorphenaminum
• Chlorpheniramine
• Chlorpheniramine polistirex
• Chlorpheniraminum
• Clorfenamina
• Clorfeniramina
• γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
• γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Chlorpheniramine gluconate	79YPK3BAIT	25387-68-2	OCMSTKFGYJZBIY-IFWQJVLJSA-N
Chlorpheniramine hydrochloride	5S6VUP419V	56343-98-7	NOXNCSQBTYNMHD-UHFFFAOYSA-N
Chlorpheniramine maleate	V1Q0O9OJ9Z	113-92-8	DBAKFASWICGISY-BTJKTKAUSA-N
Chlorpheniramine tannate	72JT935YTT	1405-56-7	KOOFUFFGNZKXFG-HBNMXAOGSA-N

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Chlorpheniramine Maleate Injection USP	Liquid	10 mg	Intramuscular; Intravenous; Subcutaneous	Omega Laboratories Ltd	Not applicable	Not applicable
Chlortripolon Inj 10mg/ml	Liquid	10 mg	Intramuscular; Intravenous; Subcutaneous	Schering Plough	1953-12-31	1999-08-04

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
4 Hour Allergy Relief	Tablet	4 mg/1	Oral	Better Living Brands	1992-12-19	Not applicable
Aller-chlor	Tablet	4 mg/1	Oral	Rugby	1992-12-19	Not applicable
Aller-chlor	Tablet	4 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	1992-12-19	2018-05-11
Aller-chlor	Tablet	4 mg/1	Oral	A S Medication Solutions	1992-12-19	2017-06-20
Aller-Chlor	Syrup	2 mg/5mL	Oral	Rugby	2003-01-17	Not applicable
Aller-chlor	Syrup	2 mg/5mL	Oral	Rugby	2014-03-20	Not applicable
Allergy	Tablet	4 mg/1	Oral	A S Medication Solutions	1992-12-19	2017-06-20
Allergy	Tablet	4 mg/1	Oral	Supervalu	1992-12-19	Not applicable
Allergy	Tablet	4 mg/1	Oral	Remedy Repack	2009-02-26	Not applicable
Allergy	Tablet	4 mg/1	Oral	Kroger	1987-07-15	2017-12-01

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
999 Cold Remedy	Chlorpheniramine maleate (2 mg/6000mg) + Acetaminophen (100 mg/6000mg)	Capsule	Oral	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	2003-07-03	Not applicable
999 Cold Remedy Granular	Chlorpheniramine maleate (4 mg/90g) + Acetaminophen (200 mg/90g)	Granule	Oral	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	2003-07-03	Not applicable
999 Ganmaoling Cold	Chlorpheniramine maleate (2 mg/1) + Acetaminophen (100 mg/1) + Caffeine (2 mg/1)	Capsule	Oral	Kingsway	2012-07-30	Not applicable
Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride	Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Tablet, coated	Oral	AAA Pharmaceutical, Inc.	2012-12-28	Not applicable
Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride	Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Tablet, coated	Oral	AAA Pharmaceutical, Inc.	2012-12-28	Not applicable
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride	Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Tablet, coated	Oral	AAA Pharmaceutical, Inc.	2012-12-28	Not applicable
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride	Chlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Tablet, coated	Oral	AAA Pharmaceutical, Inc.	2012-12-28	Not applicable
Acti PE	Chlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1)	Tablet	Oral	P & L Development, LLC	2015-02-28	Not applicable
Actifed PE	Chlorpheniramine maleate (4 mg) + Phenylephrine hydrochloride (10 mg)	Tablet	Oral	Mcneil Consumer Healthcare Division Of Johnson & Johnson Inc	Not applicable	Not applicable
Actifed PE Plus	Chlorpheniramine maleate (2 mg) + Acetaminophen (500 mg) + Phenylephrine hydrochloride (5 mg)	Tablet	Oral	Mcneil Consumer Healthcare Division Of Johnson & Johnson Inc	Not applicable	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Atuss DS Tannate Suspension	Chlorpheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (30 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)	Suspension	Oral	Atley Pharmaceuticals	2006-11-21	2017-08-29
Chlorpheniramine Maleate	Chlorpheniramine maleate (4 mg/1)	Tablet	Oral	Cardinal Health	2011-06-06	2018-01-25
DryMax	Chlorpheniramine maleate (4 mg/5mL) + Methscopolamine nitrate (1.25 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)	Syrup	Oral	Jay Mac Pharmaceuticals	2010-01-18	2016-10-13
Lexuss 210	Chlorpheniramine maleate (2 mg/5mL) + Codeine phosphate (10 mg/5mL)	Liquid	Oral	Centurion Labs	2009-04-15	2017-08-17
Poly Hist Pd	Chlorpheniramine maleate (2 mg/5mL) + Mepyramine maleate (12.5 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)	Liquid	Oral	Poly Pharmaceuticals	2004-08-05	2017-08-29
R-Tanna	Chlorpheniramine tannate (9 mg/1) + Phenylephrine tannate (25 mg/1)	Tablet	Oral	Pd Rx Pharmaceuticals, Inc.	2005-10-19	2016-12-21
R-Tanna	Chlorpheniramine tannate (9 mg/1) + Phenylephrine tannate (25 mg/1)	Tablet	Oral	Prasco, Laboratories	2005-10-19	2016-10-13
R-Tanna Pediatric Suspension	Chlorpheniramine tannate (4.5 mg/5mL) + Phenylephrine tannate (5 mg/5mL)	Suspension	Oral	Prasco, Laboratories	2010-02-03	2016-10-13
Sildec PE DM	Chlorpheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL) + Phenylephrine hydrochloride (12.5 mg/5mL)	Syrup	Oral	Rebel Distributors	2010-03-31	2017-11-04

International/Other Brands

Chlo-Amine / Chlor-Trimeton (Schering-Plough) / Clofeniramina / Haynon / Piriton (GlaxoSmithKline)

Categories

• Anti-Allergic Agents
• Antihistamines for Systemic Use
• Antipruritics
• Central Nervous System Depressants
• Combined Inhibitors of Serotonin/Norepinephrine Reuptake
• Cytochrome P-450 CYP2D6 Inhibitors
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 CYP3A7 Substrates
• Cytochrome P-450 Enzyme Inhibitors
• Dermatologicals
• Histamine Agents
• Histamine Antagonists
• Histamine H1 Antagonists
• Moderate Risk QTc-Prolonging Agents
• Neurotransmitter Agents
• OCT2 Inhibitors
• Pheniramine
• Propylamine Derivatives
• Pyridines
• QTc Prolonging Agents
• Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
• Serotonin Agents
• Serotonin Modulators
• Substituted Alkylamines

UNII

3U6IO1965U

CAS number

132-22-9

Weight

Average: 274.788
Monoisotopic: 274.123676325

Chemical Formula

C₁₆H₁₉ClN₂

InChI Key

SOYKEARSMXGVTM-UHFFFAOYSA-N

InChI

InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3

IUPAC Name

[3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine

SMILES

CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1

Pharmacology

Indication

For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.

Associated Conditions

• Allergic Rhinitis (AR)
• Allergies
• Coughing
• Pollen Allergy
• Upper respiratory symptoms

Pharmacodynamics

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H₁-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H₁-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Mechanism of action

Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

Target	Actions	Organism
AHistamine H1 receptor	antagonist	Human
USodium-dependent serotonin transporter	inhibitor	Human
USodium-dependent noradrenaline transporter	inhibitor	Human
USodium-dependent dopamine transporter	inhibitor	Human

Absorption

Well absorbed in the gastrointestinal tract.

Volume of distribution

Not Available

Protein binding

72%

Metabolism

Primarily hepatic via Cytochrome P450 (CYP450) enzymes.

Route of elimination

Not Available

Half life

21-27 hours

Clearance

Not Available

Toxicity

Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg [Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.] Also a mild reproductive toxin to women of childbearing age.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Chlorphenamine H1-Antihistamine Action	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental, Illicit
4-Methoxyamphetamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with 4-Methoxyamphetamine.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.	Experimental
Abexinostat	The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Chlorphenamine.	Investigational
Acepromazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Chlorphenamine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acetazolamide.	Approved, Vet Approved
Acetophenazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acetophenazine.	Approved
Acetylglycinamide chloral hydrate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Acetylglycinamide chloral hydrate.	Experimental
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Chlorphenamine.	Approved
Adinazolam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Adinazolam.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Adipiplon.	Investigational
Agmatine	The serum concentration of Agmatine can be increased when it is combined with Chlorphenamine.	Experimental, Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Agomelatine.	Approved, Investigational
Alaproclate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alaproclate.	Experimental
Alcaftadine	The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Chlorphenamine.	Approved
Alcuronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alcuronium.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorphenamine.	Approved, Illicit
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Chlorphenamine.	Approved, Investigational
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Chlorphenamine.	Approved, Vet Approved
Allobarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Allobarbital.	Experimental
Allopregnanolone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Allopregnanolone.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorphenamine.	Approved, Illicit, Investigational
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Chlorphenamine.	Approved
Amifampridine	The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Chlorphenamine.	Approved
Amikacin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amikacin.	Approved, Investigational, Vet Approved
Amineptine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amineptine.	Illicit, Withdrawn
Amiodarone	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Chlorphenamine.	Approved
Amitriptylinoxide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amitriptylinoxide.	Approved, Investigational
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenamine.	Approved, Illicit
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Chlorphenamine.	Approved, Investigational
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Chlorphenamine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Amperozide.	Experimental
Amphetamine	Amphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved, Illicit, Investigational
Amprenavir	The metabolism of Chlorphenamine can be decreased when combined with Amprenavir.	Approved, Investigational
Anagrelide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Anagrelide.	Approved
Aniracetam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Aniracetam.	Experimental
Antazoline	The risk or severity of QTc prolongation can be increased when Antazoline is combined with Chlorphenamine.	Approved
Apalutamide	The serum concentration of Chlorphenamine can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Chlorphenamine.	Approved, Investigational
Apramycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Apramycin.	Experimental, Vet Approved
Aprepitant	The serum concentration of Chlorphenamine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprobarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Aprobarbital.	Approved, Illicit
Apronalide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Apronalide.	Experimental
Arbaclofen Placarbil	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Arbaclofen Placarbil.	Investigational
Arbekacin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Arbekacin.	Approved, Investigational
Arformoterol	The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Chlorphenamine.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Chlorphenamine.	Approved, Investigational
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Arsenic trioxide.	Approved, Investigational
Artemether	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Artemether.	Approved
Asenapine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Asenapine.	Approved
Astemizole	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Chlorphenamine.	Approved, Investigational
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Chlorphenamine.	Approved
Atracurium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Atracurium.	Approved, Experimental, Investigational
Atracurium besylate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Atracurium besylate.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Azaperone.	Investigational, Vet Approved
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Chlorphenamine.	Approved
AZD-3043	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with AZD-3043.	Investigational
Azelastine	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Chlorphenamine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Chlorphenamine.	Approved
Barbexaclone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbexaclone.	Experimental
Barbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbital.	Illicit
Beclamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Beclamide.	Experimental
Bedaquiline	The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Chlorphenamine.	Approved
Bekanamycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bekanamycin.	Experimental
Benactyzine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benactyzine.	Withdrawn
Benmoxin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benmoxin.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benperidol.	Approved, Investigational
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Chlorphenamine.	Approved
Benzoctamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzoctamine.	Approved
Benzphetamine	The risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Benzphetamine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzyl alcohol.	Approved
Benzylpenicilloyl Polylysine	Chlorphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Bepridil	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Bepridil.	Approved, Withdrawn
Besifloxacin	The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Chlorphenamine.	Approved
Betahistine	The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorphenamine.	Approved, Investigational
Bicalutamide	The metabolism of Chlorphenamine can be decreased when combined with Bicalutamide.	Approved
Bifemelane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bifemelane.	Experimental
Bifeprunox	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bifeprunox.	Investigational
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Chlorphenamine.	Approved, Investigational
BL-1020	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with BL-1020.	Investigational
Blonanserin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Blonanserin.	Approved, Investigational
Boceprevir	The metabolism of Chlorphenamine can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Chlorphenamine.	Approved, Investigational
Bosentan	The serum concentration of Chlorphenamine can be decreased when it is combined with Bosentan.	Approved, Investigational
Botulinum Toxin Type A	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Botulinum Toxin Type A.	Approved, Investigational
Botulinum Toxin Type B	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Botulinum Toxin Type B.	Approved, Investigational
Brexpiprazole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved
Brivaracetam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brivaracetam.	Approved, Investigational
Brofaromine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brofaromine.	Experimental
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bromisoval.	Experimental
Bromperidol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Chlorphenamine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brotizolam.	Approved, Investigational, Withdrawn
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Chlorphenamine.	Approved
Bufotenine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bufotenine.	Experimental, Illicit
Buprenorphine	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The risk or severity of adverse effects can be increased when Bupropion is combined with Chlorphenamine.	Approved
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Chlorphenamine.	Approved, Investigational
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Chlorphenamine.	Approved, Illicit
Butaperazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butaperazine.	Experimental
Butethal	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorphenamine.	Approved, Illicit, Vet Approved
Butriptyline	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Butriptyline.	Approved
Camazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Camazepam.	Approved, Illicit
Cannabidivarin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cannabidivarin.	Investigational
Capreomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Capreomycin.	Approved
Captodiame	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Captodiame.	Approved, Investigational
Carbamazepine	The metabolism of Chlorphenamine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Carbinoxamine.	Approved
Carbromal	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carbromal.	Experimental
Carfentanil	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carfentanil.	Illicit, Investigational, Vet Approved
Cariprazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cariprazine.	Approved, Investigational
Carisbamate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Carisbamate.	Investigational
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Caroxazone.	Withdrawn
Cathinone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cathinone.	Illicit
Ceritinib	The serum concentration of Chlorphenamine can be increased when it is combined with Ceritinib.	Approved
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Chlorphenamine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Chlorphenamine.	Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorphenamine.	Approved, Illicit, Investigational
Chlormezanone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlormezanone.	Approved, Investigational, Withdrawn
Chloroquine	The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Chlorphenamine.	Approved, Investigational, Vet Approved
Chlorphenesin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlorphenesin.	Approved, Vet Approved, Withdrawn
Chlorphentermine	Chlorphentermine may decrease the sedative and stimulatory activities of Chlorphenamine.	Illicit, Withdrawn
Chlorproethazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlorproethazine.	Experimental
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Chlorphenamine.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Chlorphenamine.	Approved, Investigational, Withdrawn
Chlortetracycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlortetracycline.	Approved, Investigational, Vet Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorphenamine.	Approved
Choline	The serum concentration of Choline can be increased when it is combined with Chlorphenamine.	Approved, Nutraceutical
Choline salicylate	The serum concentration of Choline salicylate can be increased when it is combined with Chlorphenamine.	Approved, Nutraceutical
Cilostazol	The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Chlorphenamine.	Approved, Investigational
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Cinnarizine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cinnarizine.	Approved, Investigational
Cinolazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cinolazepam.	Approved
Cinoxacin	The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Chlorphenamine.	Approved, Investigational, Withdrawn
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Chlorphenamine.	Approved, Investigational
Cisapride	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cisapride.	Approved, Investigational, Withdrawn
Cisatracurium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cisatracurium.	Approved
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Chlorphenamine.	Approved
Citalopram	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Citalopram.	Approved
Clarithromycin	The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Chlorphenamine.	Approved
Clemastine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Clemastine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Clidinium is combined with Chlorphenamine.	Approved
Clindamycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clindamycin.	Approved, Vet Approved
Clobazam	The risk or severity of adverse effects can be increased when Clobazam is combined with Chlorphenamine.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Chlorphenamine.	Approved, Investigational, Vet Approved
Clomocycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clomocycline.	Approved
Clonazepam	The risk or severity of adverse effects can be increased when Clonazepam is combined with Chlorphenamine.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine.	Approved
Clopenthixol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clopenthixol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine.	Approved, Illicit
Clothiapine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clothiapine.	Experimental
Clotiazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clotiazepam.	Approved, Illicit
Clotrimazole	The metabolism of Chlorphenamine can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Cloxazolam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cloxazolam.	Approved, Investigational
Clozapine	The risk or severity of QTc prolongation can be increased when Clozapine is combined with Chlorphenamine.	Approved
Cobicistat	The metabolism of Chlorphenamine can be decreased when combined with Cobicistat.	Approved
Cocaine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Codeine.	Approved, Illicit
Colistimethate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Colistimethate.	Approved, Vet Approved
Colistin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Colistin.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Crizotinib	The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Chlorphenamine.	Approved
CUDC-101	The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Chlorphenamine.	Investigational
CUDC-907	The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Chlorphenamine.	Investigational
Curcumin	The metabolism of Chlorphenamine can be decreased when combined with Curcumin.	Approved, Investigational
Cyamemazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyamemazine.	Approved
Cyclizine	The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Chlorphenamine.	Approved
Cyclobarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclobarbital.	Experimental
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclobenzaprine.	Approved
Cyclopropane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclopropane.	Experimental
Cyclosporine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Chlorphenamine.	Approved
Dabrafenib	The serum concentration of Chlorphenamine can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Danazol	The metabolism of Chlorphenamine can be decreased when combined with Danazol.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.	Approved, Investigational
Dapiprazole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dapiprazole.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dapoxetine is combined with Chlorphenamine.	Investigational
Darunavir	The metabolism of Chlorphenamine can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.	Approved, Investigational
Deanol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Deanol.	Experimental
Decamethonium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Decamethonium.	Approved
Deferasirox	The serum concentration of Chlorphenamine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorphenamine.	Approved
Delamanid	The risk or severity of QTc prolongation can be increased when Delamanid is combined with Chlorphenamine.	Approved, Investigational
Delavirdine	The metabolism of Chlorphenamine can be decreased when combined with Delavirdine.	Approved
Delorazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Delorazepam.	Approved, Illicit, Investigational
Demeclocycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Demeclocycline.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Chlorphenamine.	Approved
Desipramine	The risk or severity of QTc prolongation can be increased when Desipramine is combined with Chlorphenamine.	Approved, Investigational
Desloratadine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desvenlafaxine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Detomidine.	Vet Approved
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Deutetrabenazine.	Approved, Investigational
Dexamethasone	The serum concentration of Chlorphenamine can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chlorphenamine.	Approved
Dexchlorpheniramine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dexchlorpheniramine.	Experimental, Investigational
Dexchlorpheniramine maleate	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dexchlorpheniramine maleate.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dexmedetomidine.	Approved, Vet Approved
Dextofisopam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextofisopam.	Investigational
Dextroamphetamine	Dextroamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved, Illicit
Dextromoramide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dezocine.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Chlorphenamine.	Approved, Illicit, Investigational, Vet Approved
Dibekacin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dibekacin.	Experimental
Dibenzepin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dibenzepin.	Experimental
Dichloralphenazone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dichloralphenazone.	Approved, Illicit
Diethyl ether	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Diethyl ether.	Experimental
Diethylpropion	Diethylpropion may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Difenoxin.	Approved, Illicit
Difloxacin	The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Chlorphenamine.	Vet Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydromorphine.	Experimental, Illicit
Dihydrostreptomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dihydrostreptomycin.	Investigational, Vet Approved
Diltiazem	The metabolism of Chlorphenamine can be decreased when combined with Diltiazem.	Approved, Investigational
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dimenhydrinate.	Approved
Dimetacrine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dimetacrine.	Approved, Withdrawn
Dimethyltryptamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dimethyltryptamine.	Experimental, Illicit
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Chlorphenamine.	Approved, Investigational
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorphenamine.	Approved, Illicit
Disopyramide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Disopyramide.	Approved
Dixyrazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dixyrazine.	Experimental
Dofetilide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dofetilide.	Approved, Investigational
Dolasetron	The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Chlorphenamine.	Approved, Investigational
Domoic Acid	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Domoic Acid.	Experimental
Domperidone	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Domperidone.	Approved, Investigational, Vet Approved
Donepezil	The risk or severity of QTc prolongation can be increased when Donepezil is combined with Chlorphenamine.	Approved
Dopamine	The serum concentration of Dopamine can be increased when it is combined with Chlorphenamine.	Approved
Doramectin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doramectin.	Vet Approved
Dosulepin	The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Chlorphenamine.	Approved
Dotarizine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dotarizine.	Investigational
Doxacurium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxacurium.	Approved
Doxefazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxefazepam.	Experimental
Doxepin	The risk or severity of QTc prolongation can be increased when Doxepin is combined with Chlorphenamine.	Approved, Investigational
Doxycycline	The metabolism of Chlorphenamine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved, Illicit
Dronedarone	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dyclonine.	Approved
Ebastine	The risk or severity of QTc prolongation can be increased when Ebastine is combined with Chlorphenamine.	Approved, Investigational
Ecopipam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ecopipam.	Investigational
Edivoxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Edivoxetine.	Investigational
Efavirenz	The metabolism of Chlorphenamine can be decreased when combined with Efavirenz.	Approved, Investigational
Eliglustat	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Eliglustat.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eltanolone.	Investigational
Emedastine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Emedastine.	Approved
Emepronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Emepronium.	Experimental
Emylcamate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Emylcamate.	Experimental
Enflurane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Enflurane.	Approved, Investigational, Vet Approved
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Chlorphenamine.	Approved, Investigational
Entacapone	The risk or severity of adverse effects can be increased when Entacapone is combined with Chlorphenamine.	Approved, Investigational
Entinostat	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Chlorphenamine.	Investigational
Enzalutamide	The serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide.	Approved
Eperisone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eperisone.	Approved, Investigational
Epinastine	The risk or severity of QTc prolongation can be increased when Epinastine is combined with Chlorphenamine.	Approved, Investigational
Epinephrine	The serum concentration of Epinephrine can be increased when it is combined with Chlorphenamine.	Approved, Vet Approved
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorphenamine.	Approved, Investigational
Erlotinib	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Erlotinib.	Approved, Investigational
Erythromycin	The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Chlorphenamine.	Approved, Investigational, Vet Approved
Escitalopram	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Escitalopram.	Approved, Investigational
Eslicarbazepine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eslicarbazepine.	Approved
Eslicarbazepine acetate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Esmirtazapine.	Investigational
Esreboxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Esreboxetine.	Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Chlorphenamine.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorphenamine.	Approved, Investigational
Etacrynic acid	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etacrynic acid.	Approved, Investigational
Ethadione	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethadione.	Experimental
Ethanol	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethylmorphine.	Approved, Illicit
Etifoxine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etifoxine.	Investigational, Withdrawn
Etiracetam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etiracetam.	Investigational
Etizolam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etomidate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etoperidone.	Withdrawn
Etorphine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Chlorphenamine can be decreased when it is combined with Etravirine.	Approved
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Chlorphenamine.	Approved, Investigational
Fabomotizole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fabomotizole.	Experimental
Famotidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorphenamine.	Approved
Fazadinium bromide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fazadinium bromide.	Experimental
Febarbamate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Febarbamate.	Experimental
Felbamate	The risk or severity of QTc prolongation can be increased when Felbamate is combined with Chlorphenamine.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fenyramidol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fenyramidol.	Experimental
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.	Approved
Fexofenadine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Fexofenadine.	Approved, Investigational
Fingolimod	The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Chlorphenamine.	Approved, Investigational
Flecainide	The risk or severity of QTc prolongation can be increased when Flecainide is combined with Chlorphenamine.	Approved, Withdrawn
Fleroxacin	The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Chlorphenamine.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin.	Approved, Investigational
Fluanisone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluanisone.	Experimental
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Chlorphenamine.	Approved, Investigational
Fludiazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fludiazepam.	Approved, Illicit
Flumequine	The risk or severity of QTc prolongation can be increased when Flumequine is combined with Chlorphenamine.	Withdrawn
Flunarizine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorphenamine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine.	Approved, Illicit, Investigational
Fluspirilene	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluspirilene.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chlorphenamine.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluvoxamine.	Approved, Investigational
Formoterol	The risk or severity of QTc prolongation can be increased when Formoterol is combined with Chlorphenamine.	Approved, Investigational
Fosamprenavir	The metabolism of Chlorphenamine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Chlorphenamine can be increased when it is combined with Fosaprepitant.	Approved
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Chlorphenamine.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fospropofol.	Approved, Illicit, Investigational
Framycetin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Framycetin.	Approved
Furazolidone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Furazolidone.	Approved, Investigational, Vet Approved
Fusidic Acid	The serum concentration of Chlorphenamine can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorphenamine.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gabapentin Enacarbil.	Approved, Investigational
Gaboxadol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gaboxadol.	Investigational
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Chlorphenamine.	Approved, Investigational
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Chlorphenamine.	Approved
Gallamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gallamine.	Experimental
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gallamine Triethiodide.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorphenamine.	Approved, Illicit, Investigational
Gantacurium Chloride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gantacurium Chloride.	Investigational
Garenoxacin	The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Chlorphenamine.	Investigational
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Chlorphenamine.	Approved, Investigational
Gedocarnil	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gedocarnil.	Experimental
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Chlorphenamine.	Approved, Investigational
Geneticin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Geneticin.	Experimental
Gentamicin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gentamicin.	Approved, Vet Approved
GENTAMICIN C1A	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with GENTAMICIN C1A.	Experimental
Gepefrine	Gepefrine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental
Gepirone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gepirone.	Investigational
Givinostat	The risk or severity of QTc prolongation can be increased when Givinostat is combined with Chlorphenamine.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Glutethimide.	Approved, Illicit
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorphenamine.	Approved
Granisetron	The risk or severity of QTc prolongation can be increased when Granisetron is combined with Chlorphenamine.	Approved, Investigational
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Grepafloxacin.	Approved, Investigational, Withdrawn
Guanfacine	The risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halazepam.	Approved, Illicit, Withdrawn
Halofantrine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Halofantrine.	Approved
Haloperidol	The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chlorphenamine.	Approved
Halothane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halothane.	Approved, Vet Approved
Harmaline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Harmaline.	Experimental
Heptabarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Heptabarbital.	Approved
Heroin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Heroin.	Approved, Illicit, Investigational
Hexafluronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexafluronium.	Approved
Hexamethonium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexamethonium.	Experimental
Hexapropymate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexapropymate.	Experimental
Hexobarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hexobarbital.	Approved
Histamine	The serum concentration of Histamine can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Chlorphenamine.	Approved
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenamine.	Approved, Investigational
Hydracarbazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hydracarbazine.	Experimental
Hydrocodone	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine.	Approved, Illicit
Hydroxyamphetamine	Hydroxyamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Chlorphenamine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved
Hygromycin B	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hygromycin B.	Vet Approved
Hypericin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hypericin.	Investigational
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorphenamine.	Approved, Investigational
Ibutilide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ibutilide.	Approved
Idelalisib	The metabolism of Chlorphenamine can be decreased when combined with Idelalisib.	Approved
Ifenprodil	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ifenprodil.	Approved, Investigational, Withdrawn
Iloperidone	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Iloperidone.	Approved
Imagabalin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Imagabalin.	Investigational
Imatinib	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Imatinib.	Approved
Imipramine	The risk or severity of QTc prolongation can be increased when Imipramine is combined with Chlorphenamine.	Approved
Imipramine oxide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Imipramine oxide.	Experimental
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Chlorphenamine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of QTc prolongation can be increased when Indapamide is combined with Chlorphenamine.	Approved
Indinavir	The metabolism of Chlorphenamine can be decreased when combined with Indinavir.	Approved
Indiplon	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indiplon.	Investigational
Iofetamine I-123	Iofetamine I-123 may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved
Iprindole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iprindole.	Experimental
Iproclozide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iproclozide.	Withdrawn
Iproniazid	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iproniazid.	Withdrawn
Isavuconazole	The serum concentration of Chlorphenamine can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Chlorphenamine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isepamicin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Isepamicin.	Experimental
Isocarboxazid	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Isocarboxazid.	Approved
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Chlorphenamine.	Approved, Vet Approved
Isoniazid	The metabolism of Chlorphenamine can be decreased when combined with Isoniazid.	Approved, Investigational
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Chlorphenamine.	Approved, Investigational
Itraconazole	The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Chlorphenamine.	Approved, Investigational
Ivabradine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ivabradine.	Approved
Ivacaftor	The serum concentration of Chlorphenamine can be increased when it is combined with Ivacaftor.	Approved
Ivosidenib	The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Chlorphenamine.	Approved, Investigational
Kanamycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Kanamycin.	Approved, Investigational, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ketobemidone.	Approved, Investigational
Ketoconazole	The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Chlorphenamine.	Approved, Investigational
Ketotifen	The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Chlorphenamine.	Approved
L-Tryptophan	L-Tryptophan may increase the serotonergic activities of Chlorphenamine.	Approved, Nutraceutical, Withdrawn
Lacosamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lacosamide.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine.	Approved, Investigational
Lanicemine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lanicemine.	Investigational
Lapatinib	The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Chlorphenamine.	Approved, Investigational
Lenvatinib	The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Chlorphenamine.	Approved, Investigational
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorphenamine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam.	Approved, Investigational
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Chlorphenamine.	Approved, Investigational
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Chlorphenamine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levodopa.	Approved
Levofloxacin	The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Chlorphenamine.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Chlorphenamine.	Approved, Investigational
Levomilnacipran	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomilnacipran.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorphenamine.	Approved
Lincomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lincomycin.	Approved, Vet Approved
Linezolid	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Linezolid.	Approved, Investigational
Lisdexamfetamine	Lisdexamfetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved, Investigational
Lithium carbonate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lithium carbonate.	Approved
Lithium cation	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lithium cation.	Experimental
Lofentanil	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lofentanil.	Illicit
Lofepramine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lofepramine.	Experimental
Lofexidine	The therapeutic efficacy of Chlorphenamine can be increased when used in combination with Lofexidine.	Approved, Investigational
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Chlorphenamine.	Approved, Investigational
Lopinavir	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lopinavir.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Loratadine.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorphenamine.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lormetazepam.	Approved
Lorpiprazole	The serum concentration of Chlorphenamine can be increased when it is combined with Lorpiprazole.	Approved
Lortalamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lortalamine.	Experimental
Lovastatin	The metabolism of Chlorphenamine can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Chlorphenamine.	Approved
Luliconazole	The serum concentration of Chlorphenamine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Chlorphenamine can be increased when combined with Lumacaftor.	Approved
Lumateperone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lumateperone.	Investigational
Lumefantrine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.	Approved, Investigational
Lymecycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lymecycline.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lysergic Acid Diethylamide.	Illicit, Investigational, Withdrawn
Macimorelin	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Macimorelin.	Approved, Investigational
Magnesium acetate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium acetate.	Approved
Magnesium acetate tetrahydrate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium acetate tetrahydrate.	Approved
Magnesium Aluminum Silicate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium Aluminum Silicate.	Approved
Magnesium aspartate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium aspartate.	Experimental
Magnesium carbonate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium carbonate.	Approved, Investigational
Magnesium cation	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium cation.	Approved, Nutraceutical
Magnesium chloride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium chloride.	Approved
Magnesium citrate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium citrate.	Approved
Magnesium gluconate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium gluconate.	Approved, Investigational
Magnesium glycinate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium glycinate.	Approved
Magnesium hydroxide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium orotate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium orotate.	Experimental
Magnesium oxide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium oxide.	Approved
Magnesium phosphate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium phosphate.	Experimental
Magnesium silicate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium silicate.	Approved
Magnesium stearate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium stearate.	Investigational
Magnesium sulfate	The therapeutic efficacy of Chlorphenamine can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Magnesium Trisilicate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium Trisilicate.	Approved
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Chlorphenamine.	Approved, Investigational
Mazindol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mazindol.	Approved, Investigational
Mebanazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebanazine.	Withdrawn
Mebicar	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebicar.	Experimental
Mebutamate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mebutamate.	Approved
Mecamylamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mecamylamine.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Meclizine is combined with Chlorphenamine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medetomidine.	Vet Approved
Medifoxamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Medifoxamine.	Experimental
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Chlorphenamine.	Approved, Investigational
Melatonin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melitracen	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melitracen.	Experimental, Investigational
Melperone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Melperone.	Approved, Investigational
Memantine	The serum concentration of Memantine can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Mephedrone	Mephedrone may decrease the sedative and stimulatory activities of Chlorphenamine.	Investigational
Mephenesin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mephenesin.	Approved
Mephenoxalone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mephenoxalone.	Experimental
Mephentermine	Mephentermine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved
Mephenytoin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mephenytoin.	Investigational, Withdrawn
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Meptazinol.	Experimental
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Chlorphenamine.	Approved, Vet Approved
Mequitazine	The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Chlorphenamine.	Approved
Mesoridazine	The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Chlorphenamine.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.	Approved
Metformin	The serum concentration of Metformin can be increased when it is combined with Chlorphenamine.	Approved
Methacycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methacycline.	Approved, Investigational
Methadone	The risk or severity of QTc prolongation can be increased when Methadone is combined with Chlorphenamine.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	Methamphetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methaqualone.	Illicit, Withdrawn
Metharbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metharbital.	Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Chlorphenamine.	Approved
Methotrimeprazine	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methoxyflurane.	Approved, Investigational, Vet Approved
Methoxyphenamine	Methoxyphenamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental
Methsuximide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.	Approved
Methylene blue	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylene blue.	Approved, Investigational
Methylpentynol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylpentynol.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methylphenobarbital.	Approved
Methyprylon	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methyprylon.	Approved, Illicit, Withdrawn
Metoclopramide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metoclopramide.	Approved, Investigational
Metocurine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metocurine.	Approved
Metocurine Iodide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metocurine Iodide.	Approved, Withdrawn
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Chlorphenamine.	Approved
Metyrosine	Chlorphenamine may increase the sedative activities of Metyrosine.	Approved
Mianserin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mianserin.	Approved, Investigational
Mibefradil	The metabolism of Chlorphenamine can be decreased when combined with Mibefradil.	Investigational, Withdrawn
Miconazole	The metabolism of Chlorphenamine can be decreased when combined with Miconazole.	Approved, Investigational, Vet Approved
Micronomicin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Micronomicin.	Experimental
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.	Approved, Illicit
Midomafetamine	Midomafetamine may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental, Illicit, Investigational
Mifepristone	The serum concentration of Chlorphenamine can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Milnacipran.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Minaprine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved, Investigational
Mirabegron	The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Chlorphenamine.	Approved
Mirtazapine	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Chlorphenamine can be decreased when it is combined with Mitotane.	Approved
Mivacurium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mivacurium.	Approved
MMDA	MMDA may decrease the sedative and stimulatory activities of Chlorphenamine.	Experimental, Illicit
Mocetinostat	The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Chlorphenamine.	Investigational
Moclobemide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Moclobemide.	Approved, Investigational
Modafinil	The serum concentration of Chlorphenamine can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Chlorphenamine.	Approved
Molindone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Molindone.	Approved
Moperone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Moperone.	Experimental
Moricizine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Moricizine.	Approved, Investigational, Withdrawn
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Chlorphenamine.	Approved, Investigational
Mosapramine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mosapramine.	Experimental
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorphenamine.	Approved, Investigational
MRK-409	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with MRK-409.	Experimental
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved, Investigational
Nafamostat	The serum concentration of Nafamostat can be increased when it is combined with Chlorphenamine.	Approved, Investigational
Nafcillin	The serum concentration of Chlorphenamine can be decreased when it is combined with Nafcillin.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorphenamine.	Approved
Nalidixic Acid	The risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Chlorphenamine.	Approved, Investigational
Naloxone	The metabolism of Chlorphenamine can be decreased when combined with Naloxone.	Approved, Vet Approved
Neamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neamine.	Experimental
Nefazodone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nefazodone.	Approved, Withdrawn
Nefiracetam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nefiracetam.	Investigational
Nelfinavir	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Chlorphenamine.	Approved
Nemonoxacin	The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Chlorphenamine.	Investigational
Neocitrullamon	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neocitrullamon.	Experimental
Neomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neomycin.	Approved, Vet Approved
Neosaxitoxin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Neosaxitoxin.	Investigational
Netilmicin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Netilmicin.	Approved, Investigational
Netupitant	The serum concentration of Chlorphenamine can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Chlorphenamine can be increased when combined with Nevirapine.	Approved
Nialamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nialamide.	Withdrawn
Niaprazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Niaprazine.	Experimental
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Chlorphenamine.	Approved, Investigational
Nilotinib	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Nilotinib.	Approved, Investigational
Nisoxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nisoxetine.	Experimental
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorphenamine.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorphenamine.	Approved, Vet Approved
Nomifensine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nomifensine.	Withdrawn
Nordazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nordazepam.	Approved
Norepinephrine	The serum concentration of Norepinephrine can be increased when it is combined with Chlorphenamine.	Approved
Norfloxacin	The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Chlorphenamine.	Approved
Normethadone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Chlorphenamine.	Approved
Octamoxin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Octamoxin.	Withdrawn
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorphenamine.	Approved, Investigational
Ofloxacin	The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Chlorphenamine.	Approved
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Chlorphenamine.	Approved, Investigational
Olaparib	The metabolism of Chlorphenamine can be decreased when combined with Olaparib.	Approved
Olodaterol	The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Chlorphenamine.	Approved
Olopatadine	The risk or severity of QTc prolongation can be increased when Olopatadine is combined with Chlorphenamine.	Approved
Ondansetron	The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Chlorphenamine.	Approved
Opipramol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Opipramol.	Investigational
Opium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Opium.	Approved, Illicit
Orbifloxacin	The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Chlorphenamine.	Vet Approved
Orphenadrine	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Orvepitant	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Orvepitant.	Investigational
Osanetant	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Chlorphenamine can be increased when it is combined with Osimertinib.	Approved
Oxaflozane	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxaflozane.	Experimental
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Chlorphenamine.	Approved, Investigational
Oxaprotiline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxaprotiline.	Experimental
Oxatomide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Oxatomide.	Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine.	Approved
Oxcarbazepine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxcarbazepine.	Approved
Oxiracetam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxiracetam.	Experimental
Oxitriptan	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxitriptan.	Approved, Investigational, Nutraceutical
Oxolinic acid	The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Chlorphenamine.	Experimental
Oxprenolol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxprenolol.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Oxypertine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxypertine.	Experimental
Oxytetracycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxytetracycline.	Approved, Investigational, Vet Approved
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorphenamine.	Approved, Vet Approved
Palbociclib	The serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Paliperidone.	Approved
Pancuronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pancuronium.	Approved
Panobinostat	The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Chlorphenamine.	Approved, Investigational
Papaverine	The risk or severity of QTc prolongation can be increased when Papaverine is combined with Chlorphenamine.	Approved, Investigational
Paraldehyde	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Paramethadione	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paramethadione.	Approved
Pargyline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pargyline.	Approved
Paromomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paromomycin.	Approved, Investigational
Paroxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paroxetine.	Approved, Investigational
Pasireotide	The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Chlorphenamine.	Approved
Pazopanib	The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Chlorphenamine.	Approved
Pazufloxacin	The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Chlorphenamine.	Investigational
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Chlorphenamine.	Approved
Penfluridol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Penfluridol.	Experimental
Penimepicycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Penimepicycline.	Experimental
Pentamidine	The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Chlorphenamine.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.	Approved, Vet Approved
Pentobarbital	The metabolism of Chlorphenamine can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved
Perazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perazine.	Approved, Investigational
Perflutren	The risk or severity of QTc prolongation can be increased when Perflutren is combined with Chlorphenamine.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorphenamine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Chlorphenamine.	Approved
Phenacemide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenacemide.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenazocine.	Experimental
Phencyclidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phencyclidine.	Illicit
Phenelzine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenelzine.	Approved
Phenethylamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenethylamine.	Experimental
Pheneturide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pheneturide.	Experimental
Phenibut	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenibut.	Experimental
Pheniprazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pheniprazine.	Withdrawn
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chlorphenamine.	Approved
Phenobarbital	The metabolism of Chlorphenamine can be increased when combined with Phenobarbital.	Approved, Investigational
Phenoperidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenoperidine.	Experimental
Phenoxypropazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenoxypropazine.	Withdrawn
Phenprobamate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phenprobamate.	Experimental
Phensuximide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Phensuximide.	Approved
Phentermine	Phentermine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved, Illicit
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Chlorphenamine.	Approved, Vet Approved
Pimavanserin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pimavanserin.	Approved, Investigational
Pimozide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Pimozide.	Approved
Pinazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pinazepam.	Experimental
Pipamperone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipamperone.	Approved, Investigational
Pipecuronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipecuronium.	Approved
Pipemidic acid	The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Chlorphenamine.	Experimental
Pipotiazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipotiazine.	Approved, Investigational
Piritramide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Piritramide.	Approved, Investigational
Pirlimycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pirlimycin.	Vet Approved
Pirlindole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pirlindole.	Approved
Piromidic acid	The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Chlorphenamine.	Experimental
Pitolisant	The therapeutic efficacy of Pitolisant can be decreased when used in combination with Chlorphenamine.	Approved, Investigational
Pivagabine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pivagabine.	Investigational
Pivhydrazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pivhydrazine.	Withdrawn
Pizotifen	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pizotifen.	Approved
Plazomicin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Plazomicin.	Approved, Investigational
Polymyxin B Sulfate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Polymyxin B Sulfate.	Approved, Vet Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.	Approved
Posaconazole	The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Chlorphenamine.	Approved, Investigational, Vet Approved
Pracinostat	The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Chlorphenamine.	Investigational
Pramipexole	Chlorphenamine may increase the sedative activities of Pramipexole.	Approved, Investigational
Prazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prazepam.	Approved, Illicit
Prazosin	The serum concentration of Prazosin can be increased when it is combined with Chlorphenamine.	Approved
Pregabalin	The therapeutic efficacy of Chlorphenamine can be increased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Pridinol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pridinol.	Experimental
Primaquine	The risk or severity of QTc prolongation can be increased when Primaquine is combined with Chlorphenamine.	Approved
Primidone	The metabolism of Chlorphenamine can be increased when combined with Primidone.	Approved, Vet Approved
Probucol	The risk or severity of QTc prolongation can be increased when Probucol is combined with Chlorphenamine.	Approved, Investigational
Procainamide	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Procarbazine.	Approved, Investigational
Prochlorperazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prochlorperazine.	Approved, Vet Approved
Progabide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Progabide.	Approved, Investigational
Promazine	The risk or severity of QTc prolongation can be increased when Promazine is combined with Chlorphenamine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Promethazine.	Approved, Investigational
Propafenone	The risk or severity of QTc prolongation can be increased when Propafenone is combined with Chlorphenamine.	Approved
Propanidid	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propanidid.	Experimental
Propericiazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propericiazine.	Approved, Investigational
Propiomazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propiomazine.	Approved
Propiopromazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Propiopromazine.	Vet Approved
Propofol	The risk or severity of QTc prolongation can be increased when Propofol is combined with Chlorphenamine.	Approved, Investigational, Vet Approved
Prothipendyl	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prothipendyl.	Investigational
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Chlorphenamine.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Proxibarbal.	Experimental
Prulifloxacin	The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Chlorphenamine.	Investigational
Pseudoephedrine	Pseudoephedrine may decrease the sedative and stimulatory activities of Chlorphenamine.	Approved
Psilocybine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Psilocybine.	Investigational
Puromycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Puromycin.	Experimental
Pyrantel	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pyrantel.	Approved, Vet Approved
Pyrithyldione	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pyrithyldione.	Experimental
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Chlorphenamine.	Approved, Illicit
Quetiapine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Quetiapine.	Approved
Quinidine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Quinidine.	Approved, Investigational
Quinine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Quinine.	Approved
Quinupramine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Quinupramine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ramelteon.	Approved, Investigational
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Chlorphenamine.	Approved
Ranolazine	The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Chlorphenamine.	Approved, Investigational
Rapacuronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rapacuronium.	Withdrawn
Rasagiline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rasagiline.	Approved
Reboxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Reboxetine.	Approved, Investigational
Remacemide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Remacemide.	Investigational
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Remoxipride.	Approved, Withdrawn
Reposal	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Reposal.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Chlorphenamine.	Approved, Investigational
Ribociclib	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ribociclib.	Approved, Investigational
Ribostamycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ribostamycin.	Approved, Investigational
Ricolinostat	The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Chlorphenamine.	Investigational
Rifampicin	The metabolism of Chlorphenamine can be increased when combined with Rifampicin.	Approved
Rifamycin	The metabolism of Chlorphenamine can be increased when combined with Rifamycin.	Investigational
Rifapentine	The metabolism of Chlorphenamine can be increased when combined with Rifapentine.	Approved, Investigational
Rifaximin	The metabolism of Chlorphenamine can be increased when combined with Rifaximin.	Approved, Investigational
Rilpivirine	The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Chlorphenamine.	Approved
Riluzole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Riluzole.	Approved, Investigational
Rimexolone	The metabolism of Chlorphenamine can be increased when combined with Rimexolone.	Approved
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Chlorphenamine.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ritanserin.	Investigational
Ritobegron	Ritobegron may decrease the sedative and stimulatory activities of Chlorphenamine.	Investigational
Ritonavir	The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Chlorphenamine.	Approved, Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rizatriptan.	Approved
Rocuronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rocuronium.	Approved
Rolipram	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rolipram.	Investigational
Rolitetracycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Rolitetracycline.	Approved
Romidepsin	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Romidepsin.	Approved, Investigational
Romifidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Romifidine.	Vet Approved
Ropinirole	Chlorphenamine may increase the sedative activities of Ropinirole.	Approved, Investigational
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Chlorphenamine.	Approved, Investigational
Rotigotine	Chlorphenamine may increase the sedative activities of Rotigotine.	Approved
Roxithromycin	The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Chlorphenamine.	Approved, Investigational, Withdrawn
RP-5063	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with RP-5063.	Investigational
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorphenamine.	Approved
Rufloxacin	The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Chlorphenamine.	Experimental
Rupatadine	The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Chlorphenamine.	Approved
Safinamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Safinamide.	Approved, Investigational
Safrazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Safrazine.	Withdrawn
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Chlorphenamine.	Approved, Vet Approved
Salmeterol	The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorphenamine.	Approved
Saquinavir	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Chlorphenamine.	Approved, Investigational
Sarafloxacin	The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Chlorphenamine.	Vet Approved, Withdrawn
Saredutant	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Saredutant.	Investigational
Sarilumab	The therapeutic efficacy of Chlorphenamine can be decreased when used in combination with Sarilumab.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.	Approved, Investigational
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Selegiline.	Approved, Investigational, Vet Approved
Sertindole	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Chlorphenamine.	Approved, Vet Approved
Sibutramine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sibutramine.	Approved, Illicit, Investigational, Withdrawn
Siltuximab	The serum concentration of Chlorphenamine can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Chlorphenamine can be increased when it is combined with Simeprevir.	Approved
Sisomicin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sisomicin.	Investigational
Sitafloxacin	The risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Chlorphenamine.	Experimental, Investigational
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved
Solifenacin	The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Chlorphenamine.	Approved
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Chlorphenamine.	Approved, Investigational
Sotalol	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Sotalol.	Approved
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Sparfloxacin.	Approved, Investigational
St. John's Wort	The serum concentration of Chlorphenamine can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Chlorphenamine can be increased when it is combined with Stiripentol.	Approved
Streptomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Streptomycin.	Approved, Vet Approved
Styramate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Styramate.	Experimental
Succinylcholine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Succinylcholine.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.	Approved, Investigational
Sulfamethoxazole	The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Chlorphenamine.	Approved
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Chlorphenamine.	Approved, Vet Approved
Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Chlorphenamine.	Approved, Investigational
Sulthiame	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sulthiame.	Experimental
Sultopride	The risk or severity of QTc prolongation can be increased when Sultopride is combined with Chlorphenamine.	Experimental
Sumatriptan	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Chlorphenamine.	Approved, Investigational
Suvorexant	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Talbutal	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Talbutal.	Approved, Illicit
Talopram	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Talopram.	Experimental
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Chlorphenamine.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tandospirone.	Investigational
Tandutinib	The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Chlorphenamine.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tasimelteon.	Approved, Investigational
Technetium Tc-99m ciprofloxacin	The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Chlorphenamine.	Investigational
Telaprevir	The metabolism of Chlorphenamine can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telavancin	The risk or severity of QTc prolongation can be increased when Telavancin is combined with Chlorphenamine.	Approved
Telithromycin	The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Chlorphenamine.	Approved
Temafloxacin	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Temafloxacin.	Withdrawn
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Chlorphenamine.	Approved, Investigational
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chlorphenamine.	Approved
Terfenadine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Terfenadine.	Approved, Withdrawn
Terlipressin	The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Chlorphenamine.	Approved, Investigational
Terodiline	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Terodiline.	Experimental
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Tetrabenazine.	Approved, Investigational
Tetracycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetracycline.	Approved, Vet Approved
Tetraethylammonium	The serum concentration of Tetraethylammonium can be increased when it is combined with Chlorphenamine.	Experimental, Investigational
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrahydropalmatine.	Investigational
Tetrazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrazepam.	Experimental
Tetrodotoxin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrodotoxin.	Investigational
Thalidomide	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiamylal.	Approved, Vet Approved
Thiazinam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiazinam.	Experimental
Thiethylperazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiethylperazine.	Withdrawn
Thiocolchicoside	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiocolchicoside.	Approved, Investigational
Thiopental	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiopental.	Approved, Vet Approved
Thiopropazate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiopropazate.	Experimental
Thioproperazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thioproperazine.	Approved
Thioridazine	Chlorphenamine may increase the arrhythmogenic activities of Thioridazine.	Approved, Withdrawn
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Chlorphenamine.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Tiagabine is combined with Chlorphenamine.	Approved, Investigational
Tianeptine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tianeptine.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiapride.	Approved, Investigational
Tigecycline	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tigecycline.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tilidine.	Experimental
Tipranavir	The metabolism of Chlorphenamine can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Chlorphenamine.	Approved, Investigational
Tobramycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tobramycin.	Approved, Investigational
Tocilizumab	The serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab.	Approved
Tofisopam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tofisopam.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine.	Approved, Withdrawn
Toloxatone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Toloxatone.	Approved
Tolperisone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tolperisone.	Approved, Investigational
Tolterodine	The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Chlorphenamine.	Approved, Investigational
Topiramate	The risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenamine.	Approved
Toremifene	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Toremifene.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tramadol.	Approved, Investigational
Tramiprosate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tramiprosate.	Investigational
Tranylcypromine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tranylcypromine.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trazodone.	Approved, Investigational
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Chlorphenamine.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Chlorphenamine.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tricaine methanesulfonate.	Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trichloroethylene.	Approved
Triclofos	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Triclofos.	Withdrawn
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Triflupromazine.	Approved, Vet Approved
Trimethadione	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trimethadione.	Approved
Trimethoprim	The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Chlorphenamine.	Approved, Vet Approved
Trimipramine	The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Chlorphenamine.	Approved
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Chlorphenamine.	Approved
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorphenamine.	Approved, Vet Approved
Troleandomycin	The metabolism of Chlorphenamine can be decreased when combined with Troleandomycin.	Approved
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Trovafloxacin.	Approved, Investigational, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tubocurarine.	Approved
Tucidinostat	The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Chlorphenamine.	Investigational
Valerian	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valerian.	Approved, Experimental, Investigational
Valnoctamide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valnoctamide.	Investigational
Valproic Acid	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Valproic Acid.	Approved, Investigational
Valpromide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Valpromide.	Experimental
Vancomycin	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vancomycin.	Approved
Vandetanib	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Vandetanib.	Approved
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Chlorphenamine.	Approved
Varenicline	Chlorphenamine may decrease the excretion rate of Varenicline which could result in a higher serum level.	Approved, Investigational
Vecuronium	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vecuronium.	Approved
Vemurafenib	The serum concentration of Chlorphenamine can be decreased when it is combined with Vemurafenib.	Approved
Venlafaxine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Veralipride.	Experimental
Verapamil	The metabolism of Chlorphenamine can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlorphenamine.	Approved
Vilanterol	The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Chlorphenamine.	Approved
Vilazodone	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vilazodone.	Approved
Viloxazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Viloxazine.	Approved, Investigational, Withdrawn
Vinbarbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinbarbital.	Experimental
Vinpocetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinpocetine.	Investigational
Vinyl ether	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinyl ether.	Experimental
Vinylbital	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vinylbital.	Experimental
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Chlorphenamine.	Approved, Investigational
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Chlorphenamine.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vortioxetine.	Approved, Investigational
XP19986	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with XP19986.	Investigational
Xylazine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorphenamine.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zolmitriptan.	Approved, Investigational
Zolpidem	Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenamine.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorphenamine.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

• Avoid alcohol.
• Take with food.

References

Synthesis Reference

Anil M. Salpekar, John Johnson, "Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom." U.S. Patent US4631284, issued April, 1975.

US4631284

General References

1. MSDS [Link]

External Links

Human Metabolome Database

HMDB0001944

KEGG Drug

D07398

KEGG Compound

C06905

PubChem Compound

2725

PubChem Substance

46508253

ChemSpider

2624

BindingDB

35938

ChEBI

52010

ChEMBL

CHEMBL505

Therapeutic Targets Database

DAP000336

PharmGKB

PA448960

IUPHAR

1213

Guide to Pharmacology

GtP Drug Page

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Chlorpheniramine

ATC Codes

R06AB54 — Chlorphenamine, combinations

• R06AB — Substituted alkylamines
• R06A — ANTIHISTAMINES FOR SYSTEMIC USE
• R06 — ANTIHISTAMINES FOR SYSTEMIC USE
• R — RESPIRATORY SYSTEM

R06AB04 — Chlorphenamine

• R06AB — Substituted alkylamines
• R06A — ANTIHISTAMINES FOR SYSTEMIC USE
• R06 — ANTIHISTAMINES FOR SYSTEMIC USE
• R — RESPIRATORY SYSTEM

AHFS Codes

• 04:04.20 — Propylamine Derivatives

MSDS

Download (72.8 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Healthy Volunteers	4
2	Completed	Treatment	Allergic Reactions	1
2	Recruiting	Treatment	Sunburn	1
2	Terminated	Treatment	Allergic Rhinitis (AR)	1
2	Unknown Status	Treatment	Rhinitis, Seasonal, Allergic	1
3	Unknown Status	Treatment	Acute Rhinitis / Flu-like Syndromes	1
3	Withdrawn	Treatment	Acute Rhinitis	1
4	Unknown Status	Treatment	Vitiligo	1
Not Available	Completed	Basic Science	Hypovolaemia / Temperature Change, Body	1
Not Available	Unknown Status	Prevention	Poisoning	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• Amend
• Anip Acquisition Co.
• A-S Medication Solutions LLC
• Breckenridge Pharmaceuticals
• C.O. Truxton Inc.
• Cardinal Health
• Consolidated Midland Corp.
• Contract Pharm
• Cypress Pharmaceutical Inc.
• Deltex Pharmaceuticals Inc.
• Direct Dispensing Inc.
• Dispensing Solutions
• Edwards Pharmaceuticals
• Hi Tech Pharmacal Co. Inc.
• Iopharm Laboratories Inc.
• Ivax Pharmaceuticals
• Kowa Pharmaceuticals America Inc.
• Kraft Pharmaceutical Co. Inc.
• Larken Laboratories Inc.
• Liberty Pharmaceuticals
• Magna Pharmaceuticals
• Major Pharmaceuticals
• Mallinckrodt Inc.
• McNeil Laboratories
• Meda AB
• Misemer Pharmaceuticals Inc.
• Mismer Pharmace
• Nucare Pharmaceuticals Inc.
• PD-Rx Pharmaceuticals Inc.
• Pecos Pharmaceutical Inc.
• Perrigo Co.
• Physicians Total Care Inc.
• Prepackage Specialists
• Provident Pharmaceuticals LLC
• Qualitest
• Rico Pharmacal
• River's Edge Pharmaceuticals
• Rugby Laboratories
• S&P Healthcare
• Schering-Plough Inc.
• Time-Cap Labs
• Tya Pharmaceuticals
• Watson Pharmaceuticals
• Wockhardt Ltd.

Dosage forms

Form	Route	Strength
Capsule, liquid filled	Oral
Granule, effervescent	Oral
Tablet, effervescent	Oral
Syrup	Oral	2 mg/5mL
Tablet, coated	Oral	4 mg/1
Liquid; tablet	Intramuscular; Oral; Subcutaneous
Liquid; tablet	Oral; Parenteral
Granule, for solution	Oral
Liquid	Topical
Tablet, chewable	Oral
Liquid	Oral
Suspension	Oral
Tablet, extended release	Oral	12 mg/1
Tablet, extended release	Oral	12 mg
Kit; tablet; tablet, extended release	Oral
Tablet	Oral	12 mg
Tablet, film coated, extended release	Oral	12 mg/1
Liquid	Intramuscular; Intravenous; Subcutaneous	10 mg
Syrup	Oral	2.5 mg
Kit; tablet	Oral
Kit	Oral
Kit
Tablet, extended release	Oral
Tablet, sugar coated	Oral
Lozenge	Oral	2 mg/1
Kit; powder, for solution	Oral
Kit
Liquid	Oral	2 mL/mL
Liquid	Oral	2 mg/5mL
Kit; powder	Oral
Powder, for solution	Oral
Granule	Oral
Tablet	Oral	4 mg/1
Capsule	Oral	1.25 mg/1
Capsule	Oral
Solution	Oral
Suspension, extended release	Oral
Capsule, delayed release pellets	Oral
Tablet, multilayer	Oral
Tablet	Oral	4 mg
Capsule, extended release	Oral
Powder	Oral
Tablet, film coated	Oral
Tablet	Oral
Capsule, gelatin coated	Oral
Tablet, coated	Oral
Syrup	Oral

Prices

Unit description	Cost	Unit
Ahist 12 mg tablet	1.1USD	tablet
Myci chlor-tan 8 mg caplet	0.75USD	caplet
Chlorpheniramine powder	0.67USD	g
Chlor-trimeton allergy	0.31USD	each
Chlor-trimeton 8 mg repetab	0.24USD	tablet
Aller-chlor 4 mg tablet	0.06USD	tablet
Pediacare allergy solution	0.05USD	ml
Allergy 4 mg tablet	0.04USD	tablet
Chlorpheniramine 4 mg tablet	0.02USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US7863287	No	2007-02-28	2027-02-28
US8062667	No	2009-03-29	2029-03-29
US8790700	No	2007-03-15	2027-03-15
US9066942	No	2012-01-03	2032-01-03
US6383471	No	1999-04-06	2019-04-06
US6248363	No	1999-11-23	2019-11-23
US9107921	No	2012-01-03	2032-01-03

Properties

State

Liquid

Experimental Properties

Property	Value	Source
boiling point (°C)	142 °C	Not Available
water solubility	5500 mg/L (at 37 °C)	BEILSTEIN
logP	3.38	HANSCH,C ET AL. (1995)
pKa	9.13 (at 25 °C)	PERRIN,DD (1965)

Predicted Properties

Property	Value	Source
Water Solubility	0.0519 mg/mL	ALOGPS
logP	3.74	ALOGPS
logP	3.58	ChemAxon
logS	-3.7	ALOGPS
pKa (Strongest Basic)	9.47	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	16.13 Å2	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	80.85 m3·mol-1	ChemAxon
Polarizability	30.82 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9754
Blood Brain Barrier	+	0.962
Caco-2 permeable	+	0.8749
P-glycoprotein substrate	Substrate	0.6136
P-glycoprotein inhibitor I	Non-inhibitor	0.8782
P-glycoprotein inhibitor II	Non-inhibitor	0.9376
Renal organic cation transporter	Inhibitor	0.7916
CYP450 2C9 substrate	Non-substrate	0.8026
CYP450 2D6 substrate	Substrate	0.8919
CYP450 3A4 substrate	Substrate	0.6472
CYP450 1A2 substrate	Non-inhibitor	0.9046
CYP450 2C9 inhibitor	Non-inhibitor	0.9096
CYP450 2D6 inhibitor	Inhibitor	0.8932
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.9023
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7501
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.9183
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	3.3361 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8702
hERG inhibition (predictor II)	Inhibitor	0.7145

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
GC-MS Spectrum - EI-B	GC-MS	splash10-0zfr-6290000000-2ca3230cde716588805e
Mass Spectrum (Electron Ionization)	MS	splash10-0zfr-6490000000-8e58cd1c686f23a7dac6
MS/MS Spectrum - Quattro_QQQ 10V, N/A	LC-MS/MS	splash10-01b9-3900000000-ea4ccfd2afe05f49fc7a
MS/MS Spectrum - Quattro_QQQ 25V, N/A	LC-MS/MS	splash10-004i-0090000000-9e46eb080de95d4f8f8e
MS/MS Spectrum - Quattro_QQQ 40V, N/A	LC-MS/MS	splash10-014i-1920000000-d2d2acf559d9070a1d47
MS/MS Spectrum - EI-B (Unknown) , Positive	LC-MS/MS	splash10-0zfr-6190000000-2ca3230cde716588805e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-001i-0290000000-03651b7b90a1745fdf23
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0uy0-0960000000-1f750af75fe542c6c06f
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Taxonomy

Description

This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Pyridines and derivatives

Sub Class

Pheniramines

Direct Parent

Pheniramines

Alternative Parents

Chlorobenzenes / Aralkylamines / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives

Substituents

Pheniramine / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

tertiary amino compound, pyridines, monochlorobenzenes (CHEBI:52010)

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:31